IL2 Imaging in Renal Transplantation

  • STATUS
    Recruiting
  • days left to enroll
    39
  • participants needed
    20
  • sponsor
    University Medical Center Groningen
Updated on 22 January 2021

Summary

After renal transplantation 5 to 10% of patients experience allograft rejection. Rapid and accurate diagnosis is vital for implementation of additional immunosuppressive therapy. Currently, a renal biopsy is essential for the diagnosis of renal allograft rejection. However, this is an intervention associated with complications like bleeding, patient discomfort and hospital admission. Additionally, limited biopsy sample size may lead to false negative results. So, the introduction of a new non-invasive diagnostic tool for allograft rejection could have major implications for the care of renal transplant recipients. For the purpose of visualizing infiltrating T lymphocytes with positron emission tomography (PET), the tracer 18-Fluor-Interleukin-2 ([18F]FB-IL2) has been developed. The investigators hypothesized that a high correlation exists between [18F]FB-IL2 uptake and the extend of T cell infiltration into renal transplants with signs of rejection

Details
Condition Renal Transplant Rejection, Kidney Transplant Rejection
Treatment [18F]FB-IL2 PET scan
Clinical Study IdentifierNCT03304223
SponsorUniversity Medical Center Groningen
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Female or male aged between 18 and 80 years
Renal Transplant recipients
The patient understands the purpose and risks of the study and has given written informed consent to participate in the study
All patients will have a clinical indication for renal biopsy

Exclusion Criteria

Patients with multiple-organ transplants
Female patients who are pregnant or unwilling to use adequate contraception during the study
Claustrophobia
Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
A clinical reason for an immediate start of a therapeutic intervention with immunosuppressive medication
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note